In order to further study the possible association between the anti-MDA5 Ab levels at the baseline and the severity of all the symptoms associated with anti-MDA5 DM, we classified the anti-MDA5+ patients into three clinical subgroups, as previously described [3,22]. The gene discussed is IFIH1; the disease is dermatomyositis.